OR, 95% CI and prevalence ratios of PCa and HGPCa detection at prostate biopsy across BMI groups.

BMI body mass index, OR odds ratio, CI confidence interval, PCa prostate cancer, HGPCa high-grade prostate cancer, PSA prostate specific antigen, %fPSA free PSA/total PSA (%), PV prostate volume, DRE digital rectal examination, TRUS transrectal ultrasound†Adjusted for age, PSA, %fPSA, PV, DRE, and hypoechoic TRUS nodule‡Prevalence ratios = (Probability of outcome in exposed group)/(Probability of outcome in reference group)OR, 95% CI and prevalence ratios of PCa and HGPCa detection at prostate biopsy across BMI groups.